Now Approved

In BPDCN
The Mission
To Remission
Begins Now

Introducing DECNUPAZ: Durable remission in frontline BPDCN in an outpatient setting1,2

Treatment-naïve BPDCN: 70% CR/CRc* rate (95% CI: 51.3–84.4; n/N=23/33) rapidly
achieved in 1.8 months (median time to CR/CRc [range: <0.5–4]); median
duration of CR/CRc of 9.7 months (95% CI: 2.9–NE)1†

*Remission (CR/CRc) is defined as complete remission (CR) or complete remission with
residual skin abnormality not indicative of active disease (CRc).1

†Kaplan-Meier estimate.1

View Efficacy Data

CADENZA was a multicenter, open-label, single-arm Phase 1/2 clinical trial evaluating DECNUPAZ 0.045 mg/kg IV once every 3 weeks in adults with treatment-naïve‡ BPDCN with no CNS involvement or relapsed/refractory BPDCN without evidence of active CNS disease.1,2

‡Included patients with de novo BPDCN (n=22) and patients with prior or concomitant hematologic malignancy (n=11), with no CNS involvement.1

BPDCN=blastic plasmacytoid dendritic cell neoplasm; CI=confidence interval; CNS=central nervous system; CR=complete remission; CRc=clinical complete remission; IV=intravenous; NE=not estimable

Now Approved

In BPDCN
The Mission
To Remission
Begins Now

Introducing DECNUPAZ:
Durable remission in frontline BPDCN in an outpatient setting1,2

Treatment-naïve BPDCN: 70% CR/CRc* rate (95% CI: 51.3–84.4; n/N=23/33) rapidly achieved in 1.8 months (median time to CR/CRc [range: <0.5–4]); median duration of CR/CRc of 9.7 months (95% CI: 2.9–NE)1†

*Remission (CR/CRc) is defined as complete remission (CR) or complete remission with residual skin abnormality not indicative of active disease (CRc).1

†Kaplan-Meier estimate.1

View Efficacy Data

CADENZA was a multicenter, open-label, single-arm Phase 1/2 clinical trial evaluating DECNUPAZ 0.045 mg/kg IV once every 3 weeks in adults with treatment-naïve‡ BPDCN with no CNS involvement or relapsed/refractory BPDCN without evidence of active CNS disease.1,2

‡Included patients with de novo BPDCN (n=22) and patients with prior or concomitant hematologic malignancy (n=11), with no CNS involvement.1

BPDCN=blastic plasmacytoid dendritic cell neoplasm; CI=confidence interval; CNS=central nervous system; CR=complete remission; CRc=clinical complete remission; IV=intravenous; NE=not estimable

In BPDCN
The Mission
To Remission
Begins Now

DECNUPAZ: Durable remission in frontline BPDCN in an outpatient setting1,2

Treatment-naïve BPDCN: 70% CR/CRc* rate (95% CI: 51.3–84.4; n/N=23/33) rapidly
achieved in ~2 cycles (median time to CR/CRc: 1.8 months [range: <0.5–4]); median
duration of CR/CRc of 9.7 months (95% CI: 2.9–NE)1†

*Remission (CR/CRc) is defined as complete remission (CR) or complete remission with
residual skin abnormality not indicative of active disease (CRc).1

†Kaplan-Meier estimate.1

View Efficacy Data

CADENZA was a multicenter, open-label, single-arm Phase 1/2 clinical trial evaluating DECNUPAZ 0.045 mg/kg IV once every 3 weeks in adults with treatment-naïve‡ BPDCN with no CNS involvement or relapsed/refractory BPDCN without evidence of active CNS disease.1,2

‡Included patients with de novo BPDCN (n=22) and patients with prior or concomitant hematologic malignancy (n=11), with no CNS involvement.1

BPDCN=blastic plasmacytoid dendritic cell neoplasm; CI=confidence interval; CNS=central nervous system; CR=complete remission; CRc=clinical complete remission; IV=intravenous; NE=not estimable

In BPDCN
The Mission
To Remission
Begins Now

DECNUPAZ:
Durable remission in frontline BPDCN in an outpatient setting1,2

Treatment-naïve BPDCN: 70% CR/CRc* rate (95% CI: 51.3–84.4; n/N=23/33) rapidly achieved in 1.8 months (median time to CR/CRc [range: <0.5–4]); median duration of CR/CRc of 9.7 months (95% CI: 2.9–NE)1†

*Remission (CR/CRc) is defined as complete remission (CR) or complete remission with residual skin abnormality not indicative of active disease (CRc).1

†Kaplan-Meier estimate.1

View Efficacy Data

CADENZA was a multicenter, open-label, single-arm Phase 1/2 clinical trial evaluating DECNUPAZ 0.045 mg/kg IV once every 3 weeks in adults with treatment-naïve‡ BPDCN with no CNS involvement or relapsed/refractory BPDCN without evidence of active CNS disease.1,2

‡Included patients with de novo BPDCN (n=22) and patients with prior or concomitant hematologic malignancy (n=11), with no CNS involvement.1

BPDCN=blastic plasmacytoid dendritic cell neoplasm; CI=confidence interval; CNS=central nervous system; CR=complete remission; CRc=clinical complete remission; IV=intravenous; NE=not estimable

DECNUPAZ is the
first and only
CD123‑targeting ADC
now approved for the treatment of BPDCN in adult patients1

DECNUPAZ is the
first and only
CD123‑targeting ADC
approved for the treatment of BPDCN in adult patients1

Efficacy data for treatment-naïve and relapsed/refractory BPDCN

Discover the full efficacy data from the CADENZA clinical trial

View Efficacy Data

Safety across patient populations

Learn more about adverse reactions seen in the CADENZA clinical trial

Explore Safety Data

One day.
One outpatient infusion.
Once every 21 days.

Actual clinical time may vary including premedication and post-infusion monitoring1

Continue until disease progression or unacceptable toxicity1

View Full Dosing

N C C N
Category 2A
Recommended

Pivekimab sunirine-pvzy (DECNUPAZ™) is recommended by the National Comprehensive Cancer Network® (NCCN®) as a Category 2A option for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm.3§

§Exclusion criteria for pivekimab sunirine-pvzy include: CNS involvement, history of sinusoidal obstruction syndrome (SOS), history of grade 4 capillary leak syndrome, or non‑cardiac grade 4 edema.3

A first-of-its-kind treatment

DECNUPAZ is an IgG1-based ADC designed to target CD123, delivering a payload that is a member of the IGN* class of cytotoxic molecules.1

View MOA

*Indolinobenzodiazepine pseudodimer.

ADC=antibody-drug conjugate; BPDCN=blastic plasmacytoid dendritic cell neoplasm; IgG1=immunoglobulin G1

Consider DECNUPAZ to
help patients with
BPDCN on their
mission to remission

About BPDCN